These findings suggest that taVNS may mitigate neuronal damage and improve depression-like behaviors by inhibiting excessive activation of the NF-κB/TNF-α pathway in both the prefrontal cortex and peripheral systems. The gene discussed is TNF; the disease is depressive symptom measurement.